Drugs / ADSC-SVF-002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02590042 | Oct 2017 → Oct 2020 | — | AdiSave Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADSC-SVF-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02590042 ↗ |
| Modality | Cell therapy | “As a cellular therapy product, ADSC-SVF-002 (fresh or cryopreserved) will be administered subcutaneously via injection” NCT02590042 ↗ |
| Route | Subcutaneous | “will be administered subcutaneously via injection” NCT02590042 ↗ |